SecBot SecBot

PRTA drug pipeline

$7.97
−2.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±4.0%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
5
1 bearish · 2 mixed · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2
Time to marketIf Phase 2 data in 1H 2027 is positive, the program would advance to Phase 3 trials, meaning regulatory approval and commercialization are likely several years away (late 2020s at the earliest).

moponetug Updated Oct 29

What to watch

The next major catalyst is the Phase 2 TargetTau-1 topline readout expected in 1H 2027. Positive data showing both tau biomarker clearance and cognitive benefit could validate the anti-MTBR tau approach and trigger milestone payments from BMS, while negative or mixed results would severely impair Prothena's pipeline value given the recent PRX019 termination. Watch for BMS's Q4 2026 earnings commentary for any trial timing updates.

Bull case
  • Moponetug targets tau pathology, a distinct mechanism from approved amyloid-clearing Alzheimer's drugs (Leqembi, Kisunlea), offering a potential combination or second-line approach in a massive market.
  • FDA Fast Track designation (October 2025) provides regulatory pathway advantages including rolling review and priority review eligibility.
  • BMS, a top-tier pharma partner, is fully funding development and has already paid $135 million in licensing fees, with up to $562.5 million in remaining milestones plus tiered royalties.
Bear case
  • No tau-targeting antibody has been approved for Alzheimer's to date; the biology is unproven and several prior anti-tau antibodies have failed in clinical trials.
  • The Phase 2 readout is still 6-8 months away (1H 2027), and the stock could drift lower with no near-term catalysts.
  • BMS recently terminated the PRX019 collaboration (October 28, 2026), removing up to $617.5 million in potential milestones and raising questions about BMS's commitment to the neuroscience partnership.
◆ mixed
Impact
PhasePhase 3
Time to marketIf Phase 3 succeeds, potential FDA submission would likely be in 2029-2030, with commercialization following 1-2 years later.

coramitug Updated Nov 9

What to watch

Coramitug has no near-term binary catalyst: the Phase 3 CLEOPATTRA trial's primary completion is expected in 2029. Watch for any interim analysis announcements from Novo Nordisk, which could move the stock if released early. The next major Prothena catalyst is the moponetug (PRX005) Phase 2 Alzheimer's data readout expected in 1H 2027, not coramitug.

Bull case
  • Coramitug is a potential first-in-class amyloid depleter antibody, a differentiated mechanism that directly removes amyloid deposits rather than just stabilizing TTR protein like existing therapies.
  • Phase 2 data showed statistically significant NT-proBNP reduction and improved echocardiographic parameters at the 60 mg/kg dose, with results published in Circulation (AHA's official journal).
  • FDA granted Fast Track designation in April 2026, which can accelerate development and review.
Bear case
  • Phase 2 data was described as 'mixed' by FierceBiotech, with questions about efficacy signal strength that led Novo Nordisk to advance to Phase 3 despite inconclusive results.
  • The ATTR-CM competitive landscape is intensifying: Pfizer's tafamidis (Vyndamax) is the established standard of care, Alnylam's vutrisiran (Amvuttra) was recently approved for ATTR-CM, and generics are emerging.
  • Phase 3 CLEOPATTRA trial won't read out until 2029, meaning coramitug contributes no near-term revenue or catalyst for Prothena shareholders.
● neutral
Impact
PhasePhase 3
Time to marketPhase 3 primary completion is expected in 2029. If successful, regulatory filing and potential approval would likely follow in 2030-2031 at the earliest.

prasinezumab Updated Nov 9

What to watch

The next major catalyst for prasinezumab is the Phase 3 primary completion expected in 2029, which is years away. In the nearer term, watch for any interim data updates from Roche's Phase 3 program or additional exploratory analyses presented at medical conferences. Prothena's nearer-term binary catalyst is the moponetug Phase 2 data readout expected in 1H 2027.

Bull case
  • Roche, a top-tier pharma partner, decided to advance prasinezumab into Phase 3 after reviewing the Phase IIb data, signaling confidence in the drug's potential despite the missed primary endpoint.
  • Exploratory analyses published in Nature Medicine suggested prasinezumab may slow motor progression in patients with rapidly progressing Parkinson's disease, a potentially addressable subpopulation.
  • Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody targeting a known pathological driver of Parkinson's disease, with a large addressable market if approved.
Bear case
  • The Phase IIb PADOVA study missed its primary endpoint, raising questions about whether the drug provides meaningful clinical benefit. Phase 3 is not guaranteed to succeed.
  • Phase 3 primary completion is not expected until 2029, meaning no near-term binary catalyst and a long wait for potential commercialization.
  • Prothena has no approved products and relies entirely on partner milestones and collaboration payments for revenue. The recent BMS termination of the PRX019 deal removed up to $617.5M in potential milestones.
▼ bearish
Impact
PhasePhase 1 (completed)
Time to marketNot applicable. BMS terminated the license after Phase 1; the drug is no longer in active development.

PRX019 Updated Oct 29

What to watch

PRX019 is effectively dead for Prothena after BMS's termination decision on October 28, 2026. The license agreement formally ends January 28, 2027, but no further payments are owed. All attention now shifts to the moponetug (PRX005) Alzheimer's program, where BMS is running the Phase 2 TargetTau-1 trial with data expected in H1 2027. That readout is Prothena's next major binary catalyst.

Bull case
  • Prothena retains the $80 million upfront payment BMS paid in May 2024, which provides a cash buffer.
  • The Phase 1 trial showed benign safety, no immunogenicity, and dose-dependent PK/PD meeting prespecified targets, suggesting the molecule itself was not problematic.
  • Top 10% holder William Scully has been aggressively buying PRTA shares throughout September and October 2026, investing over $8 million at prices near current levels.
Bear case
  • BMS terminated the license after Phase 1, meaning the data (while benign) did not justify further investment, casting doubt on the drug's therapeutic potential.
  • Prothena forfeits up to $617.5 million in potential milestones and tiered royalties that were a key part of the pipeline's future value.
  • The termination increases Prothena's dependence on the single moponetug (PRX005) Alzheimer's program, which is still in Phase 2 and carries its own clinical and regulatory risk.
● neutral
Impact
PhasePreclinical
Time to marketPRX012-TfR is in preclinical development with no disclosed IND filing or clinical trial start date. If preclinical work proceeds successfully, a Phase 1 trial could begin in 2027-2028, putting potential approval many years away (likely 2030+).

PRX012-TfR Updated Nov 9

What to watch

PRX012-TfR is a preclinical program with no near-term binary catalyst. Watch for any partnership announcement or IND filing as the next potential value-inflection point, but the program is likely years away from clinical data. Prothena's nearer-term value drivers are the partnered moponetug (Phase 2 readout 1H 2027) and prasinezumab/coramitug Phase 3 programs.

Bull case
  • PRX012-TfR incorporates transferrin receptor (TfR) technology designed to shuttle antibodies across the blood-brain barrier, potentially improving brain uptake and efficacy over first-generation anti-amyloid antibodies (Prothena Q4 2025 earnings call transcript, Feb 2026).
  • Prothena is 'actively advancing' the PRX012-TfR program in preclinical development, suggesting internal conviction that the TfR-enhanced format could overcome the ARIA limitations seen with PRX012 (Prothena Q4 2025 earnings call transcript, Feb 2026).
  • The Alzheimer's disease treatment market is large and growing, with approved anti-amyloid antibodies (Leqembi, donanemab) generating billions in sales, creating a substantial opportunity for a differentiated subcutaneous option with better brain penetration.
Bear case
  • PRX012's Phase 1 ASCENT data showed higher rates of brain swelling (ARIA) than approved competitors, leading Prothena to label the profile 'non-competitive' and seek partnerships rather than advance PRX012 alone (FierceBiotech, Aug 2025).
  • PRX012-TfR is still in preclinical development with no disclosed IND filing or clinical trial start date, meaning it is likely years away from generating clinical data or regulatory milestones.
  • Prothena's stock has fallen ~40% year-to-date as of Sept 2025 amid pipeline setbacks, and the company's market cap is only ~$421M, limiting its ability to fund multiple early-stage programs (Nasdaq.com, Sept 2025).

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
May 7, 2026coramitugFast Track−4.0%−11.8%